FDA Advisory Committee does not recommend LBH 589 for treatment of Multiple Myeloma - Novartis
Novartis has announced that the FDA Oncologic Drugs Advisory Committee (ODAC) did not recommend the investigational compound LBH 589 (panobinostat), a pan-deacetylase (pan-DAC) inhibitor, for patients with previously treated Multiple Myeloma when used in combination with bortezomib[and dexamethasone. Data presented at the meeting included two clinical studies evaluating LBH 589 in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory Mutiple Myeloma: a Phase III randomized, double-blind, placebo-controlled, multicenter global registration trial called PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA) and a Phase II US multicenter, single-arm, open-label study called PANORAMA-2.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins